1-4 of 4
Gavin Choy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML

Gail J. Roboz, MD, Jean-Pierre Issa, MD, David Rizzieri, MD, Wendy Stock, MD, Casey O'Connell, MD, Karen Yee, MD, Raoul Tibes, MD, Elizabeth A. Griffiths, MD, Katherine Walsh, MD, Eric J. Feldman, MD, Ellen Ritchie, MD, Arati V. Rao, MD, Richard A. Larson, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Elias Jabbour, MD, Jorge E. Cortes, MD, Aaron Schimmer, PhD, MD, Ruben A. Mesa, MD, William Blum, MD, Woonbok Chung, PhD, Sue Naim, Pietro Taverna, PhD, Yong Hao, PhD, Gavin Choy, PharmD, Mohammad Azab, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2013) 122 (21): 1548.
https://doi.org/10.1182/blood.V122.21.1548.1548
Published: 2013
Journal Articles

First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML)

Hagop M. Kantarjian, MD, Elias Jabbour, MD, Karen Yee, MD, Patricia Kropf, MD, Casey O'Connell, MD, Wendy Stock, MD, Raoul Tibes, MD, PhD, David Rizzieri, MD, Katherine Walsh, MD, Elizabeth A. Griffiths, MD, Gail J. Roboz, MD, Michael Savona, MD, Thomas Ervin, MD, Nikolai A. Podoltsev, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, William G. Wierda, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Joseph M. Brandwein, MD, Olatoyosi Odenike, MBBS, Eric J. Feldman, MD, Woonbok Chung, PhD, Sue Naim, Gavin Choy, PharmD, Pietro Taverna, PhD, Yong Hao, PhD, George Dimitrov, MD, Mohammad Azab, MD, Jean-Pierre Issa, MD
Journal: Blood
Blood (2013) 122 (21): 497.
https://doi.org/10.1182/blood.V122.21.497.497
Published: 2013
Journal Articles

Results From the Dose Escalation Phase of a Randomized Phase 1–2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML

Hagop M. Kantarjian, MD, Gail J. Roboz, MD, David A. Rizzieri, MD, Wendy Stock, MD, Casey L. O'Connell, MD, Elizabeth A Griffiths, MD, Karen Yee, MD, Raoul Tibes, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Katherine Walsh, MD, Eric Feldman, MD, Ellen Ritchie, MD, Arati Rao, MD, Carlos Decastro, MD, Aaron D. Schimmer, MD, Ruben A. Mesa, Ibrahim Syed, MBBS, Gavin Choy, PharmD, Aram Oganesian, PhD, Pietro Taverna, PhD, Mohammad Azab, MD, Woonbok Chung, PhD, Jean-Pierre Issa, MD
Journal: Blood
Blood (2012) 120 (21): 414.
https://doi.org/10.1182/blood.V120.21.414.414
Published: 2012
Journal Articles

Phase I Trial of Sphingosomal Vincristine (SV, Marqibo®) and Dexamethasone in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL).

Deborah A. Thomas, MD, Hagop M. Kantarjian, MD, Leonard Heffner, MD, Wendy Stock, MD, Guillermo Garcia-Manero, MD, Stefan Faderl, MD, Alessandra Ferrajoli, MD, Francis Giles, MD, William Wierda, MD, Farhad Ravandi-Kashani, MD, Gavin Choy, PharmD, Gregory I. Berk, MD, Susan O’Brien, MD
Journal: Blood
Blood (2006) 108 (11): 4539.
https://doi.org/10.1182/blood.V108.11.4539.4539
Published: 2006